All News
Adagene to Present at Investor and Scientific Conferences in September
Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company’s participation in several upcoming investor and scientific conferences.
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
Gracell announced that it will present updated, longer-term results from the ongoing investigator-initiated Phase 1 trial in China evaluating FasTCAR-enabled GC012F in transplant-eligible, high-risk patients with newly diagnosed multiple myeloma (NDMM). The findings will be presented in a poster presentation at the 20th International Myeloma Society (IMS) Annual Meeting, taking place September 27-30, 2023, in Athens, Greece and virtually.
CANbridge to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today announced its participation in two upcoming investor conferences.
Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference. John Gargiulo, Chief Business Officer of Ascletis, will join the fireside chat at 2:15 pm EST on Wednesday, September 13, 2023 (i.e. 2:15 am Beijing time on Thursday, September 14, 2023).
I-Mab Announces Upcoming Participation at September Conferences
I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its participation in the following conferences in September 2023.
Grit Biotechnology Announces Closing of $60 Million Series B Financing
On September 8, 2023, Grit Biotechnology announced the completion of a Series B financing round, raising over 60 million USD.
General Administration of Customs: The total value of imports and exports in the first eight months of this year was 8.27 trillion yuan, a slight decrease of 08.0%
According to the website of the General Administration of Customs on September 9, according to customs statistics, in the first eight months of this year, the total value of China's imports and exports was 7.8 trillion yuan, a slight decrease of 27.08% year-on-year.
Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia
Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.
China’s big cities promise incentives to retain foreign research centres, talent as ‘uninvestable’ spectre haunts outlook
As fears grow that the flow of foreign cash and talent into the world’s second-largest economy may slow to a trickle, two major Chinese cities have launched charm offensives to retain foreign R&D centres.
BlackRock Pulls Back From China Under Intense Pressure
BlackRock is closing its China Flexible Equity fund as of November 7, 2023, the firm announced in an August 31 shareholder letter.
